Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats

Journal of Controlled Release

Volumn 50, Issue 1-3, 1998, Pages 21-30

  Löbenberg, Raimar ^a   Araujo, Leticia ^a   Von Briesen, Hagen ^b   Rodgers, Emily ^c   Kreuter, Jörg ^a  

^a GOETHE UNIVERSITY   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

AIDS; AZT; Drug targeting; Macrophages; Nanoparticles

Indexed keywords

DOCUSATE SODIUM; DRUG CARRIER; NANOPARTICLE; POLYSORBATE 80; ZIDOVUDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM; ZETA POTENTIAL;

ANIMALS; ANTI-HIV AGENTS; CYANOACRYLATES; FEMALE; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, WISTAR; RETICULOENDOTHELIAL SYSTEM; TISSUE DISTRIBUTION; ZIDOVUDINE;

EID: 0032472296     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00105-3     Document Type: Article

References (39)

1. Bender A., Schäfer V., Steffan A., Royer C., Kreuter J., Rübsamen-Waigmann H., Briesen H.V. Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles. Res. Virol. 145:1994;215-220.
2. Gendelman H.E., Orenstein J.M., Baca L.M., Weiser B., Burger H., Kalter D.C., Meltzer M.S. The macrophage in the persistence and pathogenesis of HIV infection. AIDS. 3:1989;475-495.
3. Von Briesen H., Andreesen R., Esser R., Brugger W., Meichsner C., Becke K., Rübsamen-Waigmann H. Infection of monocytes/macrophages by HIV in vitro. Res. Virol. 141:1990;225-231.
4. Haase A.T., Henry K., Zupancic M., Sedgewick G., Faust R.U., Melroe et al H. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 274:1996;1996.
5. Roy S., Wainberg M.A. Role of the mononuclear phagocyte system in the development of acquired immunodeficiency syndrome (AIDS). J. Leukocyte Biol. 43:1989;91-97.
6. Meltzer M.S., Skillman D.R., Hoover D.L., Hanson B.D., Turpin J.A., Kalter D.C., Gendelman H.E. Macrophages and the human immunodeficiency virus. Immunol. Today. 11:1990;217-223.
7. Löbenberg R., Kreuter J. Macrophage- targeting of AZT: a promising strategy for AIDS therapy. AIDS Research and Human Retroviruses. 12:1996;1709-1715.
8. J. Kreuter, in: J. Kreuter (Ed), Nanoparticles, in Colloidal drug delivery systems, Marcel Dekker, New York, Basel, Hong Kong, 1994, pp. 219-342.
9. 14C -methacrylate) nanoparticle radioactivity after injection in rats and mice J. Pharm. Sci. 68:1979;1443-1447.
10. Tröster S.D., Müller U., Kreuter J. Modification of body distribution of poly(methyl-methacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61:1990;85-90.
11. Müller R.H., Lherm C., Herbort J., Blunk T., Couvreur P. Alkylcyanoacrylate drug Carriers: I Physicochemical characterization of nanoparticles with different alkyl chain length. Int. J. Pharm. 84:1992;1-11.
12. Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez-Decampeneere D., Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 15:1983;335-345.
13. McLeod G., Hammer S. Zidovudine: five years later. Ann. Intern. Med. 117:1992;487-501.
14. Shafer R., Kozal M., Winters M., Iversen A., Katzenstein D., Ragi et al M. Combination Therapy with Zidovudine and Didanosine Selects for Drug-Resistant Human Immunodeficiency Virus Type 1 Strains with Unique Patterns of pol Gen Mutations. J. Infect. Dis. 169:1994;722-729.
15. P. Schölmerich, E. Mutschler, G. Thews, Saquinavir, Proteasehemmer als neue Kombinationspartner, in Arzneimitteltherapie, 1996, pp. 58-60.
16. Schäfer V., Von Briesen H., Andreesen R., Steffan A.M., Royer C., Tröster S., Kreuter J., Rübsamen-Waigmann H. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm. Res. 9:1992;541-546.
17. Schäfer V., Kreuter J., Rübsamen-Waigmann H., Gerte S., Von Briesen H. Influence of HIV-infection on the phagocytic activity of monocytes/macrophages and granulocytes. Clin. Diagn. Virol. 1:1994;279-287.
18. Bender A., Von Briesen H., Kreuter J., Ducan I.B., Rübsamen-Waigmann H. Efficiency of nanoparticles as carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/ macrophages in vitro. Antimicrob. Agents Chemother. 40:1996;1467-1471.
19. Alyautdin R., Gothier D., Petrov V., Kharkevich D., Kreuter J. Analgesic activity of hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41:1995;44-48.
20. Kreuter J., Alyautdin R., Kharkevich D., Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674:1995;171-174.
21. Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., Kreuter J. Delivery of Loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14:1997;325-328.
22. L. Sachs, Angewandte Statistik. 1984, Berlin Heidelberg New York Tokyo: Springer-Verlag.
23. Douglas S.J., Illum L., Davis S.S., Kreuter J. Particle size and size distribution of poly(butyl-2-cyanoacrylate) nanoparticles. J. Col. Interf. Sci. 101:1984;149-158.
24. Lenaerts V., Nagerlkerke J.F., Van Berkel T.J.C., Couvreur P., Grislain L., Roland M., Speiser P. In vivo uptake of polyisobutylcyanoacrylate nanoparticles by the rat liver Kupffer, endothelial and parenchymal cells. J. Pharm. Sci. 73:1984;980-982.
25. Singer J.M., Adlersberg L., Hoenig E.M., Ende E., Tchorsch Y. Radiolabelled latex particles in the investigation of phagocytosis in vivo: clearance curves and histological observations. J. Reticuloendothelial Soc. 6:1969;561-589.
26. Waser P.G., Müller U., Kreuter J., Berger S., Munz K., Kaiser E., Pfluger B. Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice. Int. J. Pharm. 39:1987;213-227.
27. Kante B., Couvreur P., Lenaerts V., Guiot P., Roland M., Baudhuin P., Speiser P. Tissue Distribution of (3H) Actinomycin D adsorbed on polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 7:1980;45-53.
28. Kreuter J., Hartmann H.R. Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in Sarcoma 180-bearing mice. Oncology. 40:1983;363-366.
29. Couvreur P., Kante B., Lenaerts V., Scailteur V., Roland M., Speiser P. Tissue distribution of antitumour drugs associated with polyalkylcyanoacrylate nanoparticles. J. Pharm. Sci. 69:1980;199-202.
30. Martindale, The Extra Pharmacopoeia. Antiviral Agents, ed. J.E.F. Reynolds. Vol. 30. The Pharmaceutical Press, London, 1993, pp. 560-563.
31. Nefzger M., Kreuter J., Voges R., Liehl E., Czok R. Distribution and elimination of polymethylmethacrylate nanoparticles after peroral administration to rats. J. Pharm. Sci. 73:1984;1309-1311.
32. Borchard G., Audus K.L., Shi F., Kreuter J. Uptake of surfactant-coated poly(methyl methacrylate) - nanoparticles by bovine brain microvessel endothelial cell monolayers. Int. J. Pharm. 110:1994;29-35.
33. G. Borchard, Untersuchung von Interaktionen kolloidaler Arzneistoffträger (Nanopartikel) mit Bestandteilen des retikuloendothelialen Systems bei Ratten: Charakterisierung der die Körperverteilung beeinflussenden Faktoren. Frankfurt, 1993.
34. Phillips N., Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine aquired immunodeficiency syndrome. Blood. 79:1992;1137-1143.
35. Benatti U., Giovine M., Damonte G., Gasparini A., Scarfi S., Flora A.D., Fraternale A., Rossi L., Magnani M. Azidothymidine homodinucleotide-loaded erythrocytes and bioreactors for slow delivery of the antiretroviral drug azidothymidine. Biochem. Biophys. Res. Commun. 220:1996;20-25.
36. Von Baeyer H., Neitzel H., Nundel M., Riedel E., Schultis H. Covalent coupling of nucleosides to low density lipoprotein (LDL) generates Macrophage specific (drug)-carriers. Int. J. Clin. Pharmacol. Therap. Toxicol. 31:1993;382-386.
37. Balter M. HIV́s other immune-sytem targets: Macrophages. Science. 274:1996;1464-1465.
38. Schmitt M., Gendrault J., Schweitzer C., Steffan A., Beyer C., Royer et al C. Permissivity of primary cultures of human Kupffer cells for HIV-1. AIDS Res. Hum. Retroviruses. 6:1990;987-991.
39. Schmitt M., Steffan A., Gendrault J., Jaeck D., Royer C., Schweitzer et al C. Multiplication of human immunodeficiency virus in primary cultures of human Kupffer cells - Possible role of liver macrophages infection in the physiopathology of AIDS. Res. Virol. 141:1990;143-152.